1,156
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors

, , &
Pages 1236-1246 | Received 12 Jun 2012, Accepted 10 Sep 2012, Published online: 15 Oct 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Marwa F. Ahmed, Eman Y. Santali & Radwan El-Haggar. (2021) Novel piperazine–chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry 36:1, pages 308-319.
Read now

Articles from other publishers (4)

Sahar M. Abou-Seri, Amal A.M. Eissa, Mohamed G.M. Behery & Farghaly A. Omar. (2021) Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2. Bioorganic Chemistry 116, pages 105334.
Crossref
Neda Fayyazi, Afshin Fassihi, Somayeh Esmaeili, Salman Taheri, Jahan B. Ghasemi & Lotfollah Saghaie. (2020) Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2. International Journal of Biological Macromolecules 142, pages 94-113.
Crossref
Mahitab K. Sobhy, Samar Mowafy, Deena S. Lasheen, Nahla A. Farag & Khaled A.M. Abouzid. (2019) 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation. Bioorganic Chemistry 89, pages 102988.
Crossref
Rino Ragno, Flavio Ballante, Adele Pirolli, Richard B. WickershamIIIIII, Alexandros Patsilinakos, Stéphanie Hesse, Enrico Perspicace & Gilbert Kirsch. (2015) Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors: development and validation of predictive 3-D QSAR models through extensive ligand- and structure-based approaches. Journal of Computer-Aided Molecular Design 29:8, pages 757-776.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.